⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205820 | 0.90 | — | — | |
| SCHEMBL207900 | 0.76 | GRM2 (0.30) | — | |
| SCHEMBL3785117 | 0.72 | KMT2A (0.34) | — | |
| SCHEMBL208845 | 0.72 | HDAC3 (0.33) | — | |
| SCHEMBL17894521 | 0.71 | MIF (0.36) | — | |
| SCHEMBL3777967 | 0.71 | SCN2A (0.32) | — | |
| SCHEMBL3778075 | 0.71 | TP53 (0.31) | — | |
| SCHEMBL15876020 | 0.69 | MAPT (0.39) | — | |
| SCHEMBL3784231 | 0.69 | MT-CO2 (0.31) | — | |
| SCHEMBL3396674 | 0.69 | SLC9A1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088941-B2 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2012-01-03 | — | — | US | disclosed |
| US-20080312188-A1 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2008-12-18 | — | — | US | disclosed |
| US-7378432-B2 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2008-05-27 | — | — | US | disclosed |
| EP-1824468-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | Tel Aviv University Future Technology Development L.P. (IL) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006054298-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2006-05-26 | — | — | WO | disclosed |
| US-20060069066-A1 | 3-(4-(3-guanidinophenyl)-1,2,3-triazol-1-yl)benzyl phosphoric acid hydrochloride; obesity, non-insulin dependent diabetes mellitus, insulin-dependent condition, affective disorder, neurodegenerative diseases, psychotic disease; compounds having hydrophobic moiety to a terminus of a peptide GSK-3 | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. | 2006-03-30 | — | — | US | disclosed |